Rare and Orphan Disease Therapeutics M&A update, 14–28 September 2026
This bi-weekly report tracks price moves, company news, and M&A activity across rare and orphan disease therapeutics companies for September 14–28, 2026, for investors, operators and advisers who need a fast read on what changed and why it matters.
For information only. Not an appraisal or a fairness opinion.
The deeper read: Rare and Orphan Disease Therapeutics Sector Outlook — September 2026
Key figures
- Sector median move
- -5.0%
- close-to-close, Sep 14–28, 2026
- S&P 500 return
- +0.8%
- same two-week period
- Sionna Therapeutics (SION) move
- -38.0%
- two-week period
- Sector median EV / Revenue
- 4.7x
- CY2027E
Read the report
1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS
Executive summary
Over September 14–28, 2026, 28 of 39 covered rare and orphan disease therapeutics names fell, with a median move of -5.0% against a +0.8% S&P 500 return, associated with programme and regulatory news rather than broad market sentiment. Programme-stage names including Sionna Therapeutics (-38.0%) and Crescent Biopharma (-26.2%) carried the deepest markdowns.
Key findings
- 28 of 39 covered names fell in the period; the median move was -5.0%
- Programme-stage names carried the deepest markdowns, led by -38.0% and -26.2%
- PTC Therapeutics completed the period's sole agreed transaction, a Fabry gene therapy deal
- Commercial franchises and programme-stage pipelines still price on separate bases
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS
Cover slide introducing the bi-weekly rare and orphan disease therapeutics update for September 14–28, 2026.
We open this bi-weekly update on rare and orphan disease therapeutics, covering what changed, who moved, what transacted, and what it means for the two weeks ending September 28, 2026. That framing sets up how we read the period's evidence on the pages that follow.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › RARE AND ORPHAN DISEASE THERAPEUTICS Pipeline Names Take the Markdown While a Commercial Buyer Steps Forward This update covers rare and orphan disease therapeutics from September 14–28, 2026: the period's movers, the company news behind them, and the one transaction the companies themselves announced. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
- 02THE BI-WEEKLY BOTTOM LINE
Programme News Got Priced Hard While a Commercial Owner Kept Buying
Summarizes the two-week period: sector-wide declines against a rising broad market, and one agreed transaction.
We find 28 of the 39 covered names fell over the period, with a median move of -5.0% against a +0.8% return for the S&P 500 — so the pressure sat inside the sector, not the broader market. Programme-stage names carried the deepest markdowns, while one commercial-stage owner completed an agreed transaction in the same window. That combination — pipeline repricing alongside a commercial buyer still active — is the throughline we carry through the rest of this update, and it tells us where capital is discriminating within the sector.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Programme News Got Priced Hard While a Commercial Owner Kept Buying The two-week period in one page · 39 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 28 of 39 Covered Names Fell; The Median Move Was -5.0% The S&P 500 returned +0.8% over the same two-week period, so the pressure sat inside the sector rather than across the market. Eleven covered names still finished higher. 2 Programme-Stage Names Carried the Period's Deepest Markdowns Sionna Therapeutics, Inc. (SION) finished -38.0%, Crescent Biopharma, Inc. (CBIO) -26.2%, Wave Life Sciences Ltd. (WVE) -19.9% and Pharvaris N.V. (PHVS) -17.9%. SION's worst single session was -17.0% on Sep 18; CBIO's was -13.7% on Sep 23. 3 One Agreed Transaction Landed: PTC Closed on a Fabry Gene Therapy PTC Therapeutics, Inc. (PTCT) completed its acquisition of the ST-920 Fabry disease gene therapy on Sep 21. It is the period's only company-announced transaction in the set, and it came from a commercial-stage rare-disease owner rather than a development-stage platform. 4 The Standing Split Between Pipelines and Commercial Franchises Held NeuraCap's standing view prices this sector on CY2027E EV / Revenue, with a 4.7x sector median and a 19.8x Premium-tier median against 1.7x at the Discount tier. This period's evidence — programme-stage drawdowns alongside a commercial buyer closing a purchase — is consistent with that split rather than a challenge to it. +12.0% Best mover — Gyre Therapeutics, Inc. (GYRE) worst: SION -38.0% · 11 up / 28 down of 39 covered -5.0% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 1 Company filings in the window 8-K events read for driver attribution
- 03PUBLIC MARKET MOVERS
Programme Updates, Not the Market, Set the Price This Period
Shows the period's largest price moves and ties them to the company news and filings recorded in the window.
We tie each of the period's biggest moves to the filings and headlines recorded in the window, using a materiality bar of 9.6% on a sector-relative basis. Sionna Therapeutics led the downside at -38.0%, followed by Crescent Biopharma at -26.2%, Wave Life Sciences at -19.9%, and Pharvaris at -17.9%, each following programme-specific news rather than a market-wide move. Where no driver is recorded in the window, we say so rather than guess. This tells us the period's price action was a read on pipeline data, not sentiment.
Everything on this page
PUBLIC MARKET MOVERS Programme Updates, Not the Market, Set the Price This Period Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -5.0% · S&P 500 +0.8% · materiality bar ±9.6% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -5.0% Sionna Therapeutics, Inc. (SION) -38.0% Shares moved following Sionna's Sep 14 plan to advance the SION-451 plus SION-2222 dual combination into a Phase 2a proof-of-concept trial, supported by post hoc sweat chloride analyses; investor-alert notices followed from Sep 15. Combination plans in cystic fibrosis get judged on the strength of the underlying evidence, not on the trial design alone. COMPANY-SPECIFIC Crescent Biopharma, Inc. (CBIO) -26.2% No notable in-window news was identified that clearly explains the move. At -26.2%, the decline ran well below the -5.0% median for covered names. Premium-tier valuations leave the least room for error when the covered set is heading lower. UNEXPLAINED Wave Life Sciences Ltd. (WVE) -19.9% Shares moved following the Sep 23 announcement that Wave initiated a Phase 2a combination trial of WVE-007 with tirzepatide in obesity — the same session as the -9.2% single-day move. A new chief business officer was named Sep 22. A platform pointed at a large indication can dilute the rare-disease premium investors were paying for. COMPANY-SPECIFIC Gyre Therapeutics, Inc. (GYRE) +12.0% No notable in-window news was identified that clearly explains the move. At +12.0%, Gyre Therapeutics, Inc. (GYRE) finished well above the -5.0% median for covered names, with a +7.2% session on Sep 17. Core-tier commercial names traded to their own rhythm while programme-stage peers repriced. UNEXPLAINED
- 04MAJOR NEWS & INDUSTRY CATALYSTS
A Clinical Hold, a Litigation Calendar, and a Label Expansion Cut Loose
Lists the two-week period's highest-impact company events, including a clinical hold, litigation calendar entries and a label expansion decision.
We rank the period's highest-impact events — a clinical hold, a litigation calendar update, and a label expansion decision among them — and link each to its underlying filing or article. Every 'why it matters' line is our read of the recorded evidence, built from a fixed source order of SEC filings, press releases and established outlets. This gives us a fact-checked view of what actually moved the sector's regulatory and legal calendar this period.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS A Clinical Hold, a Litigation Calendar, and a Label Expansion Cut Loose The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · NEWS · GlobeNewsWire Aardvark faces a securities class action over ARD-101 safety statements before the Phase 3 pause The complaint concerns safety representations that preceded a Phase 3 pause and a full FDA clinical hold on ARD-101. Lead-asset concentration converts a single regulatory setback into a whole-company diligence question. Sep 14 · NEWS · Newsfile Corp Law firm reminds Aardvark investors of the October 13, 2026 lead plaintiff deadline The litigation calendar now sits alongside the clinical calendar at Aardvark Therapeutics, Inc. Common Stock. That combination tends to shape the timing and leverage of any financing or partnering conversation. Runway decisions get harder when a company is managing a legal timetable and a regulatory one together. Sep 15 · 8-K · SEC EDGAR BioMarin discontinues VOXZOGO development in children with Noonan syndrome BioMarin Pharmaceutical Inc. (BMRN) cited feasibility and the current treatment landscape, not safety or efficacy. Franchise value stays anchored to the indications a company already treats when expansion economics do not clear. Sep 15 · NEWS · PRNewsWire Investors in Aardvark notified of a pending securities fraud class action Multiple firms circulated notices in the same few days, which keeps the ARD-101 clinical hold in front of the market. Sustained attention on a single disclosure raises the evidentiary bar for the company's next update. The market is treating regulatory status changes in orphan programmes as the key credibility test. Sep 15 · NEWS · GlobeNewsWire Investor rights firm flags the October 13, 2026 deadline in the Aardvark action The repeated notices mark how much of the period's sector news flow came from one company's regulatory setback rather than from operating progress. That imbalance is part of why the covered set finished lower. When news flow is dominated by setbacks, operating progress elsewhere gets less credit than usual. Sep 15 · NEWS · GlobeNewsWire Shareholder rights firm opens lead plaintiff process in the Aardvark securities action For the sector, the signal is procedural rather than scientific: the ARD-101 hold now has a formal legal track. Counterparties assessing the asset will want the regulatory correspondence before anything else. Regulatory correspondence quality is doing more work in diligence than the headline data set.
- 05M&A & STRATEGIC ACTIVITY
A Commercial Rare-Disease Owner Adds a Fabry Gene Therapy
Covers the period's one company-announced transaction and the broader precedent-transaction record.
We record one agreed transaction in the window: PTC Therapeutics completed its acquisition of the ST-920 Fabry disease gene therapy. It sits against a precedent set of 40 recorded deals, giving us a current reference point for how gene-targeted rare-disease assets are being valued by a commercial buyer. No older transactions are re-presented as news here, so this page reflects only what closed in this period. That tells us commercial-stage owners are still willing to add gene therapy assets even as programme-stage names get marked down.
Everything on this page
M&A & STRATEGIC ACTIVITY A Commercial Rare-Disease Owner Adds a Fabry Gene Therapy September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 21 · PTC Therapeutics, Inc. (PTCT) PTC Therapeutics, Inc. (PTCT) completes its acquisition of ST-920, a gene therapy for Fabry disease A commercial rare-disease owner adding a gene-targeted asset in a genetically defined indication. The read is appetite for assets that can plug into an existing patient-services hub and established payer relationships. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against
- 06WHAT IT MEANS
What the Period Changes for Operators, Buyers and Advisers
Translates the period's evidence into observations for operators, acquirers and advisers.
We read this period as consistent with programme and regulatory news, not commercial execution, moving prices for owners and operators. For acquirers, PTC's completed purchase of the ST-920 Fabry therapy adds a current reference point against a trailing record of 40 transactions. For advisers, the clearest story to carry into a room is the split itself: 28 of 39 names down at a -5.0% median, against a commercial buyer still active. These are observations drawn from the recorded evidence, not recommendations, and they tell us where the sector's risk and opportunity currently sit.
Everything on this page
WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisers The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 4.7x 38 companies in the study 3 valuation tiers Standing thesis: Rare and Orphan Disease Therapeutics Split Between Pipelines and Orphan Commercialization FOR OWNERS & OPERATORS The Moves Tracked Programme News; The Operating Engine Is Still the Differentiator Companies in the space traded on trial plans and regulatory status this period, not on commercial execution. FOR ACQUIRERS One Completed Purchase, and a Wider Gap Between Programme Risk and Commercial Franchises PTC's completion of the ST-920 Fabry acquisition adds a current reference point for gene-targeted rare assets bought by a commercial owner; the record now carries 40 trailing transactions. FOR ADVISORS Lead with the Split: Programme-Stage Repricing Against Commercial Buyers Acting The period's evidence is specific and easy to carry into a board room: 28 of 39 covered names fell with a -5.0% median, the deepest moves followed programme and regulatory news, BioMarin discontinued a Noonan syndrome expansion on feasibility grounds
- 07SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
Explains the sources and methodology behind every figure and claim in the update.
We build every figure in this update from a traceable record — SEC filings, publisher-sourced news, and market data through September 28, 2026 — so each figure links back to its source. This keeps our driver attributions calibrated to recorded evidence rather than asserted causation. Readers can therefore check any number in this deck against its underlying filing or article.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Rare and Orphan Disease Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 1 name below the floor was excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T183036Z_560_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · newsfilecorp.com · sec.gov · prnewswire.com
Sources and methodology
This update covers Rare and Orphan Disease Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 39 listed companies whose core business is Rare and Orphan Disease Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Aardvark Therapeutics, Inc. Common Stock (AARD), Agios Pharmaceuticals, Inc. (AGIO), Alnylam Pharmaceuticals, Inc. (ALNY), BridgeBio Pharma, Inc. (BBIO), BioCryst Pharmaceuticals, Inc. (BCRX), BioMarin Pharmaceutical Inc. (BMRN), Crescent Biopharma, Inc. (CBIO), Corcept Therapeutics Incorporated (CORT), Design Therapeutics, Inc. (DSGN), Dyne Therapeutics, Inc. (DYN), Eton Pharmaceuticals, Inc. (ETON), Edgewise Therapeutics, Inc. (EWTX), Fulcrum Therapeutics, Inc. (FULC), Gyre Therapeutics, Inc. (GYRE), Harmony Biosciences Holdings, Inc. (HRMY), Larimar Therapeutics, Inc. (LRMR), Mirum Pharmaceuticals, Inc. (MIRM), PepGen Inc. (PEPG), Pharming Group N.V. (PHAR), Pharvaris N.V. (PHVS), ProQR Therapeutics N.V. (PRQR), PTC Therapeutics, Inc. (PTCT), Protagonist Therapeutics, Inc. (PTGX), Palvella Therapeutics, Inc. (PVLA), Ultragenyx Pharmaceutical Inc. (RARE), Rigel Pharmaceuticals, Inc. (RIGL), Atrium Therapeutics, Inc. (RNA), Rhythm Pharmaceuticals, Inc. (RYTM), Rezolute, Inc. (RZLT), Septerna Inc (SEPN), Sionna Therapeutics, Inc. (SION), Sarepta Therapeutics, Inc. (SRPT), Savara Inc. (SVRA), Entrada Therapeutics, Inc. (TRDA), Travere Therapeutics, Inc. (TVTX), United Therapeutics Corporation (UTHR), Vanda Pharmaceuticals Inc. (VNDA), Vertex Pharmaceuticals Incorporated (VRTX), Wave Life Sciences Ltd. (WVE). 1 name below the floor was excluded from the statistics: GANX.
Window and company universe
This update covers Rare and Orphan Disease Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 39 listed companies whose core business is Rare and Orphan Disease Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Aardvark Therapeutics, Inc. Common Stock (AARD), Agios Pharmaceuticals, Inc. (AGIO), Alnylam Pharmaceuticals, Inc. (ALNY), BridgeBio Pharma, Inc. (BBIO), BioCryst Pharmaceuticals, Inc. (BCRX), BioMarin Pharmaceutical Inc. (BMRN), Crescent Biopharma, Inc. (CBIO), Corcept Therapeutics Incorporated (CORT), Design Therapeutics, Inc. (DSGN), Dyne Therapeutics, Inc. (DYN), Eton Pharmaceuticals, Inc. (ETON), Edgewise Therapeutics, Inc. (EWTX), Fulcrum Therapeutics, Inc. (FULC), Gyre Therapeutics, Inc. (GYRE), Harmony Biosciences Holdings, Inc. (HRMY), Larimar Therapeutics, Inc. (LRMR), Mirum Pharmaceuticals, Inc. (MIRM), PepGen Inc. (PEPG), Pharming Group N.V. (PHAR), Pharvaris N.V. (PHVS), ProQR Therapeutics N.V. (PRQR), PTC Therapeutics, Inc. (PTCT), Protagonist Therapeutics, Inc. (PTGX), Palvella Therapeutics, Inc. (PVLA), Ultragenyx Pharmaceutical Inc. (RARE), Rigel Pharmaceuticals, Inc. (RIGL), Atrium Therapeutics, Inc. (RNA), Rhythm Pharmaceuticals, Inc. (RYTM), Rezolute, Inc. (RZLT), Septerna Inc (SEPN), Sionna Therapeutics, Inc. (SION), Sarepta Therapeutics, Inc. (SRPT), Savara Inc. (SVRA), Entrada Therapeutics, Inc. (TRDA), Travere Therapeutics, Inc. (TVTX), United Therapeutics Corporation (UTHR), Vanda Pharmaceuticals Inc. (VNDA), Vertex Pharmaceuticals Incorporated (VRTX), Wave Life Sciences Ltd. (WVE). 1 name below the floor was excluded from the statistics: GANX.
How the moves and statistics are computed
Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.
Events, news and how a move is attributed
Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.
Transactions in the window and the trailing record
Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.
Sources
Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.
Interpretation and important notice
'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.
Sources linked in the report
- -38.0% (globenewswire.com)
- -26.2% (globenewswire.com)
- -19.9% (globenewswire.com)
- Aardvark faces a securities class action over ARD-101 safety statements (globenewswire.com)
- Law firm reminds Aardvark investors of the October 13, 2026 lead plaintiff (newsfilecorp.com)
- BioMarin discontinues VOXZOGO development in children with Noonan syndrome (sec.gov)
- Investors in Aardvark notified of a pending securities fraud class action (prnewswire.com)
- Investor rights firm flags the October 13, 2026 deadline in the Aardvark (globenewswire.com)
- Shareholder rights firm opens lead plaintiff process in the Aardvark (globenewswire.com)
- PTC Therapeutics, Inc. (PTCT) completes its acquisition of ST-920, a gene therapy for Fabry (prnewswire.com)
- globenewswire.com (globenewswire.com)
- prnewswire.com (prnewswire.com)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Sector Outlook · 29 September 2026Rare and Orphan Disease Therapeutics Sector Outlook — September 2026
- M&A Update · 29 September 2026Regenerative Medicine M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Regenerative Medicine Sector Outlook — September 2026
- M&A Update · 29 September 2026Specialty and Branded Pharmaceuticals M&A update, 14–28 September 2026
Want this analysis for a company in Rare and Orphan Disease Therapeutics?
Company valuation reports run the same method against a single business — public or private.
